Company intelligence / Profile preview

Tatsumi Kagaku

Kanazawa, Ishikawa, Japan

Ownership: Private
Employees: ~450
Development stage: Other

Overview

Tatsumi Kagaku manufactures and sells around 170–200 types of generic pharmaceuticals, mainly targeting digestive and circulatory ailments. The company is enhancing production capacity with a new GMP-compliant plant and focuses on both domestic and export markets

Therapeutic areas: CardiovascularGastroenterology
Modalities: Small molecule
Industry: Chemicals & Materials

Partnerships

Japan Economic Research Institute Inc. (consulting/advisory)

Beyond the preview

Go deeper on Tatsumi Kagaku.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tatsumi Kagaku.

Explore the full profile